Insider buying last 90 days
No open-market insider purchases were filed for HCA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 16 close
HCA Healthcare's recent news flow centers on fund positioning and continued scrutiny of its July 2026 guidance cut. Intech Investment Management reduced its stake by 51.3% in the third quarter, though the same report noted quarterly earnings of $7.22 per share and revenue of $19.85 billion, both ahead of expectations. The JPMorgan Active Value ETF listed HCA as a lead net buy on 11 November. Pomerantz Law Firm disclosed an investigation tied to the payer-mix-driven guidance reduction from July, while HCA also received recognition as a top employer for veterans. An SVP sale of $1.77 million in shares on 10 November followed an earlier stock appreciation rights award.
HCA closed at $511.78, up 2.6%, sitting above both its 50-day average of $454.91 and 200-day average of $445.44, with the shorter average above the longer one, reflecting a supportive trend. The GekkoIndex reads 48.9, placing it in the Neutral zone. Price stands 29.3% above Gekko Fair Value of $395.75, a notable gap.
Over the next 20 trading days, earnings are not due until 26 January 2027, outside this window. Smart-money activity shows one Congressional buy and no sales in the past 90 days. Seasonality over five years shows an average gain of 2.7% across this stretch, rising in 4 of those years. Analyst consensus target sits at $477.27, implying downside of 6.7% from current levels.
Written by AI from the Nov 16, 2026 close and checked automatically against the figures on this page.
HCA Healthcare scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
Above 50 and 200-day
Close $511.78 is above the 50-day ($454.91) and 200-day ($445.44) averages, and the 50-day is above the 200-day.
See the chart48.9, Neutral
Reading 48.9 is in the Neutral zone.
See the GekkoIndex30.7% above
Price is 30.7% above Gekko Fair Value (more than 5% above).
See fair valueLeans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart moneyReports in 70 days
Next report Jan 26, 2027, 70 days away — outside a typical 20-trading-day hold.
See earnings+1.3% on average
From this point in the calendar, the next 20 trading days averaged +1.3% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
HCA Healthcare closed at $511.78 on Nov 16, 2026, +8.1% over the past year, inside a 52-week range of $353.99 to $556.52.
Use the left and right arrow keys to read daily values.
Put HCA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
HCA Healthcare provides a wide range of medical services across the United States through its subsidiaries. Its hospitals handle general and acute care, including inpatient treatment, intensive and cardiac care, diagnostics, and emergency medicine, while also supporting outpatient services such as ambulatory surgery, lab work, imaging, respiratory and physical therapy, and cardiology. Beyond hospital campuses, the company runs standalone surgery and emergency centers, urgent care and walk-in clinics, imaging and rehabilitation sites, oncology and radiation facilities, and physician offices.
The company also operates psychiatric hospitals offering treatment for children, adolescents, and adults, along with programs addressing alcohol and drug dependency. Its facilities are grouped into general and acute care hospitals, psychiatric hospitals, and rehabilitation hospitals, supported by a large number of freestanding surgery and endoscopy centers spread across multiple states and England, serving patients who need both hospital-based and outpatient medical care.
HCA Healthcare was founded in 1968 and was previously known as HCA Holdings, Inc. It is headquartered in Nashville, Tennessee, and its shares are listed on the NYSE under the ticker HCA.
HCA Healthcare’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 48.9, in the Neutral zone, up 1.9 points over five sessions.
Up 1.9 points over five sessions.
Reading for Nov 16, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 60 | 0.0% | −0.4% | ||
| Accumulation | 143 | +0.4% | +1.2% | ||
| Neutral (current zone) | 435 | +0.8% | +1.8% | ||
| Distribution | 66 | −0.6% | +3.8% | ||
| Selling | 3 | Too few readings yet | |||
Average HCA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
HCA Healthcare trades 30.7% above Gekko Fair Value of $391.47, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what HCA Healthcare shares are worth, recalculated every trading day.
$391.47
Gekko Fair Value, Nov 17, 2026
30.7% Overvalued
At the end of Aug 2026 the price was 4.4% above the estimate.
No open-market insider purchases were filed for HCA Healthcare, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for HCA in the last 90 days.
From Form 4 filings, dated to when each was filed.
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 4 |
From congressional disclosures, which report amounts as ranges.
HCA Healthcare has been buying back its own shares.
From company filings.
2of the funds Gekko tracks hold HCA.
HCA Healthcare reports on Jan 26, 2027 (70 days away), and beat the EPS estimate in 6 of its last 8 reports.
Jan 26, 2027
70 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 24, 2026 | $7.59 est $7.57 | $20.23B est $19.76B | +3.5% |
| Apr 24, 2026 | $7.15 est $7.15 | $19.11B est $19.09B | −6.0% |
| Jan 27, 2026 | $8.01 est $7.46 | $19.51B est $19.68B | +4.0% |
| Oct 24, 2025 | $6.96 est $5.79 | $19.16B est $18.60B | +6.3% |
| Jul 25, 2025 | $6.84 est $6.29 | $18.61B est $18.50B | −0.3% |
| Apr 25, 2025 | $6.45 est $5.75 | $18.32B est $18.26B | −2.8% |
| Jan 24, 2025 | $6.22 est $6.14 | $18.29B est $18.23B | +2.0% |
| Oct 25, 2024 | $4.88 est $4.98 | $17.49B est $17.54B | −10.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for HCA Healthcare is $483.41, −5.5% from the last close, from 16 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 16 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 11 | Mizuho Securities | $570 | +11.4% |
| Nov 5 | Bank of America Securities | — | — |
| Nov 4 | Bernstein | $471 | −8.0% |
| Nov 2 | Wells Fargo | $468 | −8.6% |
| Oct 29 | Morgan Stanley | $380 | −25.7% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 17, HCA Healthcare averaged +1.3% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.1% | 3 of 5 |
| Next 10 trading days | +1.0% | 3 of 5 |
| Next 15 trading days | +1.0% | 3 of 5 |
| Next 20 trading days | +1.3% | 3 of 5 |
| Next 30 trading days | +1.6% | 3 of 5 |
For scale, HCA’s typical 20-trading-day move in either direction is about 6%.
HCA Healthcare’s market cap is $106.9B, with a P/E ratio of 16.6 and revenue of $78.70B over the last twelve months.
Coverage of HCA Healthcare this week reads positive: 7 positive, 6 neutral and 2 negative headlines.
HCA Healthcare’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| THCTenet Healthcare | Neutral | 1.0% below |
| UHSUniversal Health Services | Neutral | 9.5% below |
| PACSPACS | Neutral | 6.2% below |
| CHEChemed | Neutral | 2.6% below |
| SGRYSurgery Partners | Distribution | 42.5% above |
| NHCNational HealthCare | Accumulation | 18.8% above |
A peer links to its own page where one exists.
HCA Healthcare’s market cap is $106.9B at the Nov 16, 2026 close of $511.78, with 208.9M shares outstanding. The shares trade on a P/E ratio of 16.6.
The consensus analyst 12-month price target for HCA Healthcare is $483.41, −5.5% from the last close. Of the 16 firms that rated the stock in the last 90 days, 8 rate it a buy, 7 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate HCA Healthcare is overvalued: the Nov 16, 2026 close of $511.78 is 30.7% above Gekko Fair Value of $391.47. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
HCA Healthcare is expected to report on Jan 26, 2027 (70 days away). Analysts expect earnings of $8.17 per share on revenue of $20.02B. HCA Healthcare beat the earnings estimate in 6 of its last 8 reports, moving 4.4% on average across the report.
HCA Healthcare’s 52-week high is $556.52 and its 52-week low is $353.99; it closed at $511.78 on Nov 16, 2026, +8.1% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, smart money, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,476 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.